Kamlesh Khunti1,2, Samuel Seidu3,2, Setor Kunutsor4, Melanie Davies3,2. 1. Leicester Diabetes Centre, Leicester General Hospital, Leicester, U.K. kk22@leicester.ac.uk. 2. Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K. 3. Leicester Diabetes Centre, Leicester General Hospital, Leicester, U.K. 4. School of Clinical Sciences, University of Bristol, Southmead Hospital, Southmead, U.K.
Abstract
OBJECTIVE: A previous study suggests an association between poor medication adherence and excess mortality in chronic disease. The purpose of this study was to assess the association between medication adherence and risk of cardiovascular disease (CVD), all-cause mortality, and hospitalization in type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted an electronic search on many electronic databases from inception to 27 April 2016. We selected randomized controlled trials and case-control and cohort studies reporting on CVD, all-cause mortality, or hospitalization outcomes by adherence in adults with type 2 diabetes. Two reviewers independently screened for eligible studies and extracted outcome data. Pooled relative risks (RRs) were calculated using a random-effects meta-analysis; risk of bias in each of the included studies was assessed using the GRADE approach. RESULTS: Eight observational studies were included (n = 318,125). The mean rate of poor adherence was 37.8% (95% CI 37.6-38.0). Adjusted estimates were provided by five studies only. The RRs of good (≥80%) versus poor adherence to medication were 0.72 (95% CI 0.62-0.82, I2 = 0%, three studies) for all-cause mortality and 0.90 (0.87-0.94, I2 = 63%, seven studies) for hospitalization. No evidence of small study bias was observed. Only one study reported CVD outcomes by adherence. CONCLUSIONS: We identified no trials reporting on outcomes by adherence, suggesting a systematic failure to include this information. Pooled estimates from available observational studies suggest that good medication adherence is associated with reduced risk of all-cause mortality and hospitalization in people with type 2 diabetes, although bias cannot be excluded as an explanation for these findings.
OBJECTIVE: A previous study suggests an association between poor medication adherence and excess mortality in chronic disease. The purpose of this study was to assess the association between medication adherence and risk of cardiovascular disease (CVD), all-cause mortality, and hospitalization in type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted an electronic search on many electronic databases from inception to 27 April 2016. We selected randomized controlled trials and case-control and cohort studies reporting on CVD, all-cause mortality, or hospitalization outcomes by adherence in adults with type 2 diabetes. Two reviewers independently screened for eligible studies and extracted outcome data. Pooled relative risks (RRs) were calculated using a random-effects meta-analysis; risk of bias in each of the included studies was assessed using the GRADE approach. RESULTS: Eight observational studies were included (n = 318,125). The mean rate of poor adherence was 37.8% (95% CI 37.6-38.0). Adjusted estimates were provided by five studies only. The RRs of good (≥80%) versus poor adherence to medication were 0.72 (95% CI 0.62-0.82, I2 = 0%, three studies) for all-cause mortality and 0.90 (0.87-0.94, I2 = 63%, seven studies) for hospitalization. No evidence of small study bias was observed. Only one study reported CVD outcomes by adherence. CONCLUSIONS: We identified no trials reporting on outcomes by adherence, suggesting a systematic failure to include this information. Pooled estimates from available observational studies suggest that good medication adherence is associated with reduced risk of all-cause mortality and hospitalization in people with type 2 diabetes, although bias cannot be excluded as an explanation for these findings.
Authors: Megan Hoopes; Heather Angier; Lewis A Raynor; Andrew Suchocki; John Muench; Miguel Marino; Pedro Rivera; Nathalie Huguet Journal: J Am Med Inform Assoc Date: 2018-10-01 Impact factor: 4.497
Authors: Lee Ling Lim; Eric S H Lau; Alice P S Kong; Melanie J Davies; Naomi S Levitt; Björn Eliasson; Carlos A Aguilar-Salinas; Guang Ning; Yutaka Seino; Wing Yee So; Margaret McGill; Graham D Ogle; Trevor J Orchard; Philip Clarke; Rury R Holman; Edward W Gregg; Juan José Gagliardino; Juliana C N Chan Journal: Diabetes Care Date: 2018-06 Impact factor: 19.112
Authors: Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse Journal: Diabetologia Date: 2018-12 Impact factor: 10.122
Authors: Caitrin W McDonough; Kyle Babcock; Kristen Chucri; Dana C Crawford; Jiang Bian; François Modave; Rhonda M Cooper-DeHoff; William R Hogan Journal: Pharmacoepidemiol Drug Saf Date: 2020-08-26 Impact factor: 2.890